Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Annexon (Nasdaq: ANNX) granted equity inducement awards to three new non-executive employees under its 2022 Employment Inducement Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4). The awards cover options for 243,000 shares at a $5.21 exercise price, with a ten-year term and four-year vesting schedule.
Positive
- None.
Negative
- None.
News Market Reaction – ANNX
In the May 19 session, ANNX declined 1.01%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 2026 earnings | Positive | +3.1% | Quarterly results with portfolio progress and cash runway into H2 2027. |
| May 06 | Conference presentation | Neutral | -0.3% | Announcement of Bank of America healthcare conference presentation and webcast. |
| Apr 08 | Conference appearance | Neutral | +1.5% | Needham virtual healthcare conference presentation and webcast availability. |
| Mar 30 | FY 2025 earnings | Positive | +11.7% | Year-end 2025 results with strong cash position and 2026 milestones. |
| Mar 16 | Inducement grant | Neutral | -1.9% | Single-employee inducement option grant under 2022 plan with standard vesting. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent earnings and pipeline updates with solid cash runway have generally seen positive price reactions, while routine conference and inducement grant news have had smaller, mixed moves.
Over the last few months, Annexon has focused on advancing its neuroinflammatory pipeline and reinforcing its balance sheet. Q4 2025 and Q1 2026 results highlighted late-stage programs, with cash of $238.3 million at 12/31/2025 and $225.0 million at 3/31/2026, supporting runway into the second half of 2027. Conference appearances in April and May 2026 and a prior March 2026 inducement grant reflected ongoing investor engagement and equity-based hiring. Today’s new inducement grants fit this pattern of routine corporate updates rather than major pipeline or financial catalysts.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 11, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
In the aggregate, the new non-executive employees received options to purchase 243,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
